Liquid biopsy testing has continued to revolutionize diagnostics and personalized medicine; from the integration of AI and automation to elevate liquid biopsy capabilities, to the approval of MRD as an endpoint in Multiple Myeloma.
Servier’s recent approval of vorasidenib for Grade 2 IDH-mutant glioma has sparked renewed hope in a space that has long struggled with limited treatment options.
A dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining, screening, discovery and selection from ROR1, uPAR, B7-H3, NECTIN-4, CAIX and more.
This year’s all-new agenda offers unprecedented detail on optimizing digital innovation, working with regulatory and legal review partners, and exploring how to establish a culture on innovation.
As the NK community remains determined as ever to prove the advantages of NK cells, the year of the ‘bounce back’ now feels within reach.
This conference is designed to enhance clinical practice to care for patients with cardiac implantable devices.
Mark your calendars and make plans to join your colleagues in San Diego, CA, from March 10–14, for AAOS 2025
Our goal is to collaboratively design robust potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies.
As the cell and gene therapy (CGT) pipeline matures and new, exciting technologies scale into the clinic
This event for the UK MedTech sector to showcase the latest advancements, innovations, and strategies in medical technology development and manufacturing.
Get the April 2024 brochure
delivered straight to your inbox!
